source
- Molecular residual disease testing offers earlier insight into cancer treatment responseIn oncology, determining whether cancer has truly been eliminated after therapy is challenging because imaging and standard clinical criteria often miss low‑level disease. Molecular residual diseas…
- Frazier Life Sciences raises over $1.1 billion for its public biotech fund, now $2.8 billion totalFrazier Life Sciences announced that its public fund has secured more than $1.1 billion in new capital, bringing the fund’s total assets to $2.8 billion. The fund, launched in 2021, targets small-…